Tibetan political leader slams Chinese ambassador's remarks on Dalai Lama's reincarnation
Taking to social media recently, the Chinese diplomat shared that the Dalai Lama has no authority to decide whether the reincarnation system will continue or not. This comes after the exiled Tibetan spiritual leader announced on July 2 that the 600-year-old institution of the Dalai Lama will continue and that Gaden Phodrang Trust has sole authority to recognise the future reincarnation.
Sikyong Penpa Tsering said, 'The social media post by the ambassador is ignorant of the very concept of reincarnation, because the whole purpose of reincarnation is for a spiritually realised person to decide where he or she should be reborn to carry on the responsibilities or activities of the previous life or lives.'
Sikyong said that the post, in fact, reflects complete ignorance of the very notion of reincarnation and the reason and objective behind it. 'For a government that does not believe in any religion, being responsible for recognition and forcing Lamas inside to be part of that decision-making process is pitiful,' Tsering said.
Taking to X, ambassador Xu Feihong shared that in fact, as a unique succession method of Tibetan Buddhism, the practice of Living Buddha reincarnation has continued over 700 years. 'Currently, there are over 1,000 reincarnation systems of Living Buddhas in Xizang and Tibetan-inhabited prefectures/counties of Sichuan, Yunnan, Gansu and Qinghai provinces. The 14th Dalai Lama is part of this long-standing historical tradition and religious succession, not otherwise. The reincarnation of Dalai Lamas neither began from him nor will end due to him. He has no authority to decide whether the reincarnation system shall continue or be abolished,' he added.
In his July 2 statement, the Dalai Lama said his decision was influenced by numerous requests from Tibetan spiritual leaders, members of the Tibetan Parliament-in-exile, and the Buddhist diaspora in the Himalayas, Mongolia, the Russian Federation and Asia, including mainland China, that the institution should continue.
The spiritual leader reiterated that the Gaden Phodrang Trust has sole authority to recognise the future reincarnation and no one else has any such authority to interfere in this matter. After this announcement, an irate Beijing, which describes the Dalai Lama as a 'separatist', countered that the spiritual leader's reincarnation 'must be approved by the central (Chinese) government'.
The process of recognising the reincarnations of lamas in Tibetan Buddhism is solely and uniquely a Tibetan religious tradition. In contrast, China maintains that the process of selecting his successor must adhere to Chinese law, asserting its control over Tibetan Buddhism and rejecting any succession beyond its authority.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
15 minutes ago
- Business Standard
Best of BS Opinion: India's growth story needs harmony, not exits
There are some mornings when you catch a group of teens with mismatched instruments rehearsing in the park. An off-key trumpet, a scratched-up guitar, and sometimes one hesitant drummer. It sounds like noise at first. But wait a few minutes and suddenly, the pieces fall in place. The rhythm kicks in, the melody gels, and something real begins. Not perfect, but promising. That's when the choice appears: sharpen the sound, perfect the sync, or walk away. Let's dive in. India faces that very choice across vastly different stages. The ASEAN Free Trade Agreement which came into force in 2010 and is currently under review, might seem like a discordant alliance to some. Domestic lobbies want out, citing dumped Chinese goods and lagging farm exports. But as our first editorial argues, that's like quitting the band when your mic isn't loud enough. Instead, India should fine-tune the rules, harmonise better with the region, and use the pact as a strategic amplifier in the Indo-Pacific. Then there's the Gini index, a stat that suggests India is one of the world's most equal countries. Cue the applause? Not quite. As our second editorial explains, consumption-based metrics mask deep distortions. Behind the curtain, rural-urban divides blare on like untuned basslines, and state-by-state income variations clash like overlapping tempos. To fix the score, India must orchestrate policies that bridge regions and generate inclusive growth before the dissonance drowns the melody. M Govinda Rao shows Karnataka as a cautionary concert. Bengaluru leads with unicorns and tech gigs, while North Karnataka stays muted, underfed and overlooked. Historical baggage, lopsided investment, and uneven governance have turned one state into two different playlists. It's time policymakers re-tune subsidies and capital flows, and let every region play its own solo. Meanwhile, Ajay Kumar's column on undersea cables reminds us that even backstage tech can make or break a performance. These digital lifelines, vital for India's data-heavy future, are exposed to sabotage and surveillance. Without tighter laws, more repair ships, and Quad-aligned strategy, India's internet symphony risks being cut mid-note. And Devangshu Datta's review of Commanded by Destiny: A General's Rise from Soldier to Statesman by General S M Shrinagesh brings us back to the roots: a soldier-statesman's memoir that echoes with history's crescendos and silent interludes. It's a reminder that enduring legacy, like good music, requires discipline, foresight and knowing when to let each instrument lead. Stay tuned, and remember, because the band's off-sync, don't quit on the song. Just rehearse harder!
India.com
16 minutes ago
- India.com
India's Pharma War Zone: How Delhi's Bulk Drug Push Is Rattling China
New Delhi: The heat is rising in India's pharmaceutical backrooms. Quiet factories. Long shifts. New chemical reactors humming across Himachal, Gujarat and Telangana. Something has shifted. China, long the uncontested supplier of India's drug ingredients, is suddenly nervous. Its prices are falling. Fast. Some slashed by 50%. This is no coincidence. The trigger? India's Rs 6,940 crore Production-Linked Incentive (PLI) scheme. Launched in March 2020, it was a shot across the bow. And the target: reduce dependence on Chinese Active Pharmaceutical Ingredients (APIs). By December 2024, 48 domestic API projects were sanctioned. Of these, 34 are already operational. Together, they cover 25 key drug molecules. The investment so far? Rs 4,254 crore. But the Chinese are not backing down quietly. They are throwing prices into free fall. Landed costs of certain APIs from China have collapsed far deeper than Indian prices. Take Atorvastatin, used in cholesterol pills, for instance. Indian API prices fell 17% to Rs 10,000 per kg. China pushed it down to Rs 8,000 per kg. That is a 33% crash. Let's understand with another example of Ofloxacin, a broad-spectrum antibiotic. Indian prices dropped from Rs 3,200 to Rs 2,700. China? Rs 2,100. Down 30% in a year. This is price war, not coincidence. Bhavin Mukund Mehta, director of the Kilitch Drugs and Vice Chairman of Pharmexcil, minced no words, 'Even though the PLI has helped reduce the prices of domestically-produced APIs, the Chinese players are undercutting the competition in specific product categories to retain their market share.' Behind the scenes, policymakers are reviewing the PLI's next phase. They are asked industry insiders for help. The mission is to stop China's dumping spree, push for stronger local production and close the gaping supply chain hole exposed during COVID. The Department of Pharmaceuticals is now asking – can India stand on its own chemical legs and can it stop the bleed from Beijing's pricing games? The pressure is on. China still supplies around 70% of India's API imports. India imports about 50% of its total bulk drug needs. That is the strategic choke point the PLI is aiming to break. The scheme covers the production period from FY23 to FY29. But the impact is already being felt. Jatish Sheth, secretary general of the Confederation of Indian Pharmaceutical Industry, sees this as China's last stand. 'It is an expected move from the Chinese exporters to bring down the bulk drugs prices. While their focus is to retain the market share, we believe that this is a temporary phenomenon. We do not expect the Chinese players to keep selling the drugs at such low prices for too long.' He is betting on patience. Indian drugmakers are playing the long game. With new infrastructure, newer molecules and tighter government support, the tide could soon turn. But for now, it is a staring contest across lab benches and import docks. On one side, old Chinese dominance. On the other, rising Indian ambition backed by billions. And in between? A market worth tens of billions and the chemical backbone of the world's pharmacy.
Economic Times
36 minutes ago
- Economic Times
Trump's silent economic war on China: How he's cornering Xi Jinping one nation at a time
Donald Trump is reportedly broadening his trade war with China by imposing tariffs on Asian nations like Japan and South Korea. Simultaneously, deals are being pursued with countries including Indonesia and Thailand. This strategy aims to isolate China by restricting access to crucial Asian markets that bolster its export-driven economy. Tired of too many ads? Remove Ads Donald Trump Targeting Asia to Corner Beijing Setting the Tone with Vietnam and the UK Tired of too many ads? Remove Ads Donald Trump Cracking Down on Transshipments More Asian Countries on Trump's Notice China's Growth Model Hinges on Exports Tired of too many ads? Remove Ads FAQs US president Donald Trump is quietly expanding his trade war with China by targeting the entire Asian region through a series of new tariff deals, as per a though the US reached a recent pact with Beijing, Trump is imposing fresh tariffs on countries like Japan and South Korea while pushing for agreements with Indonesia, Thailand, Cambodia, and others, according to The Telegraph successful, this strategy would trap Xi Jinping's China by cutting off key Asian markets that support Beijing's export-driven economy , as per the report. Economist at Capital Economics, Neil Shearing, pointed out that 'What we are witnessing is no passing trade war,' and added that, 'Rather, it is the manifestation of a deeper, more durable superpower rivalry between the world's two largest economies,' as quoted in The Telegraph READ: Billionaires ditch Nvidia for this AI stock that's soared 2,000% since 2023 Trump's earlier deals with the UK and Vietnam set the tone for his plan to weaken Beijing's trading power, according to the report. The UK agreement allows the White House to 'veto' Chinese investment in Britain, while the Vietnam deal cracks down on China's tactic of sending goods through Vietnam to avoid US tariffs, as per The Telegraph instance, Trump imposed a 40% tariff on 'transshipments', goods imported into Vietnam mostly from China, then exported to the US, which is double the 20% tariff on Vietnamese-made products. This sends a clear message to Hanoi that Vietnam is welcome to export to the US if it can cope with a 20% levy, Trump will come down on the country like a tonne of bricks if it replaces 'Made in Vietnam' stickers with 'Made in China,' as reported by The READ: Craving McDonald's snack wraps? They are back — with bold new flavors you need to try Trump is now threatening steep tariffs on Malaysia, Indonesia, Thailand, and Cambodia if they don't make trade deals soon, with levies as high as 36% on some countries, as these measures are expected to further squeeze China's export reach, according to the was Trump's early candidate for this strategy because, since Trump first came to power in 2017, China's machinery and electrical goods shipments to Vietnam have increased from just 17% of its total exports to nearly half, as reported by The Telegraph. After Trump returned to the White House this year, Vietnam's imports of these goods from China rose by nearly a quarter, as per the READ: Linda Yaccarino resigns: What drove the X CEO to step down and what's her net worth? Xi's strategy is to keep China's economy increasing by at least 5% a year due to the exports to Asia, reported The Telegraph. Beijing increases its GDP by pumping subsidies and investments into manufacturing, as Chinese households simply don't spend enough to allow consumption to power the economy, as reported by The Telegraph.A senior research fellow at the think tank Chatham House, David Lubin explained that, 'Whenever Chinese domestic spending growth sags, export growth accelerates,' adding, 'And that's simply because Chinese companies can't sell stuff domestically, so they sell it abroad,' as quoted in the economic model has led to overcapacity and oversupply, which has forced businesses into damaging price wars, and if these companies are not able to export their surplus to Asia, supply gluts appear inevitable, as reported by The READ: New Mexico flooding: Emergency declared - track maps, road closures and all the details He's trying to block China from using Asian markets to fuel its export-heavy penalizing Vietnam with 40% tariffs if it helps China dodge US tariffs by re-exporting Chinese goods.
